Sweet revenge on cancer: How studying sugars may change the practice of oncology

The Role of Cell Surface Sugars

• 💡 Glycobiology focuses on sugar molecules, which are crucial for cell recognition and communication, especially in the immune system.
• 🔬 All cells are coated in complex carbohydrates (sugars), forming a molecular landscape or 2D barcode that carries biological information, like blood types.
• 🧠 Historically, the function of these cell surface sugars was poorly understood, but modern science reveals their intricate roles beyond just food.

Cancer's Immune Evasion Strategy

• ⚠️ Cancer cells exhibit dramatic changes in their surface sugars, specifically an overgrowth of P-sialic acids, forming a "tropical jungle."
• 🛡️ These dense P-sialic acid coatings bind to SIGLEC receptors on immune cells, delivering an inhibitory signal that effectively puts the immune system "to sleep."
• 🎭 This mechanism allows cancer cells to escape immune recognition and destruction, enabling tumor growth and spread.

Advancing Immunotherapy Approaches

• 📈 Existing cancer immune therapies (checkpoint inhibitors) block certain inhibitory pathways, but they are not effective for over half of patients with metastatic melanoma and even fewer for other cancers.
• 🎯 The limitation of current therapies is that they often don't address the P-sialic acid-SIGLEC interaction, leaving a significant immune evasion pathway unblocked.

A Novel "Lawnmower" Therapy

• 🛠️ A new therapeutic strategy involves creating "lawnmower" molecules, which are antibody-sialidase fusion proteins.
• ✂️ These molecules are designed to cut P-sialic acids off cancer cells, making them "taste bad" to the immune system and restoring immune recognition.
• ✅ Pre-clinical studies in mouse models show that this "lawnmower" approach significantly inhibits tumor growth and, when combined with conventional immune therapy, can cure all mice.

Future Outlook and Challenges

• 🚀 Paleon Pharmaceuticals is developing an "eagle molecule" based on this concept, with a human phase one clinical trial planned for Q2 2025.
• 💬 While promising, potential autoimmune side effects are anticipated, similar to current immune therapies, requiring careful monitoring.
• 🧬 The therapy aims to improve response rates, acknowledging that cancer's heterogeneity and evolutionary adaptation mean no single treatment will cure all cancers.